Seek Labs Joins Global African Swine Fever Research Alliance (GARA)
September 16, 2024
Seek Labs is excited to announce its participation in the Global African Swine Fever Research Alliance (GARA), a global collaborative effort dedicated to fighting African Swine Fever (ASF). With its innovative CRISPR-based therapeutic technology platform, Seek Labs is set to play a pivotal role in developing next-generation solutions for ASF detection, management, and eradication.
African Swine Fever, a highly contagious viral disease affecting pigs, has caused substantial economic losses worldwide. GARA was established to address this growing crisis by uniting global leaders in research, science, and technology. GARA promotes cooperation, fosters technical exchanges, and drives the development of cutting-edge solutions to mitigate ASF’s impact, including vaccines and advanced diagnostic strategies.
As a GARA participant, Seek Labs will contribute expertise in developing innovative therapeutics for ASF through their CRISPR-based technology platform. The company’s precise technology targets and disrupts the ASF genome, which enables the host to better fight the disease. The programmable CRISPR technology can be leveraged to deliver precise therapeutics rapidly and at scale. Seek Labs recently completed a preliminary in vivo trial and demonstrated their proprietary CRISPR platform extended survival and reduced viral load in pigs infected with ASF.
The collaboration with GARA emphasizes the importance of pooling expertise and resources across industries to tackle the complex global challenge of ASF. Seek Labs hopes to bring a new dimension to the alliance’s efforts by focusing on pharmaceutical innovations that harness the power of CRISPR to deliver rapid, scalable, and targeted ASF therapeutics. By joining GARA, Seek Labs affirms its commitment to advancing animal health and preserving vital protein sources around the globe. The company’s CRISPR-based platform offers a transformative tool in the fight against ASF, positioning Seek Labs as a key contributor to global efforts to control and eradicate this devastating disease.